Weight-loss surgery down 25 percent as anti-obesity drug use soars (2024)
(news.harvard.edu)
A new study examining a large sample of privately insured patients with obesity found that use of drugs such as Ozempic and Wegovy as anti-obesity medications more than doubled from 2022 to 2023. During that same period, there was a 25.6 percent decrease in patients undergoing metabolic bariatric surgery to treat obesity.
A new study examining a large sample of privately insured patients with obesity found that use of drugs such as Ozempic and Wegovy as anti-obesity medications more than doubled from 2022 to 2023. During that same period, there was a 25.6 percent decrease in patients undergoing metabolic bariatric surgery to treat obesity.